Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge. Speaking on "Bloomberg Open Interest," Muller also discusses the implications for Novo Nordisk. (Source: Bloomberg)
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。